Prosz, Aurel
Duan, Haohui
Tisza, Viktoria
Sahgal, Pranshu
Topka, Sabine
Klus, Gregory T.
Börcsök, Judit
Sztupinszki, Zsofia
Hanlon, Timothy
Diossy, Miklos
Vizkeleti, Laura
Stormoen, Dag Rune
Csabai, Istvan
Pappot, Helle
Vijai, Joseph
Offit, Kenneth
Ried, Thomas
Sethi, Nilay
Mouw, Kent W.
Spisak, Sandor
Pathania, Shailja
Szallasi, Zoltan
Funding for this research was provided by:
Kræftens Bekæmpelse (R340-A19380, R281-A16566)
Velux Fonden (00018310, 00018310)
NIH core (P30 CA008748)
MSKCC bladder SPORE (CA221745)
National Cancer Institute (R01CA272657)
National Research Development and Innovation Office Hungary (FK142835)
The National Cancer Institute (R15 CA 235436-01)
Research and Technology Innovation Fund (KTIA_NAP_13-2014-0021)
Breast Cancer Research Foundation (BCRF-21-159)
Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant (NNF15OC0016584)
Department of Defense through the Prostate Cancer Research Program (W81XWH-18-2-0056)
Sundhed og Sygdom, Det Frie Forskningsråd (7016-00345B)
Article History
Received: 8 August 2023
Accepted: 20 November 2023
First Online: 23 November 2023
Competing interests
: K.W.M—Consulting or Advisory Role: EMD Serono, Pfizer. Research Funding: Pfizer. Patents: Institutional patents filed on <i>ERCC2</i> mutations and chemotherapy response (KW.M, Z.S., J.B, Zs. Sz. and M.D.). JV, ST and KO are inventors on a patent application for use of Illudin class of alkylating agents in patients harboring mutations in the <i>ERCC3</i> gene (PCT/US2018/022588). D.R.S: Research Funding: Pfizer, EMD Serono.H.P.: Research funding from Pfizer and Merck Z.S: Research funding from Lantern Pharma Inc.. Other authors do not have competing interest.